As part of the oral abstract podium session at the 2018 meeting of the Society of Urologic Oncology (SUO), Dr. Kim Chi from the British Columbia Cancer Agency presented a second interim analysis of long-term PROs from the LATITUDE trial. For this analysis, the median follow-up was 41 months, as opposed to 30.9 months in the initial interim analysis. To measure these patient-reported outcomes, surveys were administered to the men enrolled in this trial at baseline (before initiation of treatment), monthly during cycles 2-13, and then every 2 months until treatment discontinuation. These surveys included the Brief Pain Inventory-Short form (BPI-SF), Brief Fatigue Inventory (BFI), and Functional Assessment of Cancer Therapy – Prostate (FACT-P). Changes in these patient-reported outcomes from baseline were then measured and compared.
Chi and colleagues found that treatment was still ongoing in 34% of patients in the ADT + abiraterone + prednisone group, while only 12% of the ADT + placebo group had ongoing treatment. Over 90% of patients in both groups participated in the PRO questionnaires. Patients that were in the ADT + Abiraterone + Prednisone group showed a statistically significant decrease in the risk of progression for pain intensity, pain interference, fatigue intensity, and fatigue interference as compared to the ADT + Placebo group. Additionally, there was a delay in the time to health-related quality of life degradation in the ADT + abiraterone + prednisone group as compared to the ADT + placebo group. Chi also noted that there was a significantly greater improvement from baseline in all PRO measures in the ADT + abiraterone + prednisone group as compared to the ADT + placebo group. He concluded that patients with newly-diagnosed, castrate-sensitive, metastatic prostate cancer who use ADT + abiraterone + prednisone fare better in PROs than patients taking ADT + a placebo. These findings, combined with the demonstrated survival benefits supports the use of ADT + abiraterone + prednisone in men with newly-diagnosed metastatic castrate-sensitive prostate adenocarcinoma.
Presented By: Kim Chi, MD, British Columbia Cancer Agency, Vancouver, British Columbia
Written by: Brian Kadow, MD, Society of Urologic Oncology Fellow, Fox Chase Cancer Center, Philadelphia, PA, at the 19th Annual Meeting of the Society of Urologic Oncology (SUO), November 28-30, 2018 – Phoenix, Arizona